We have shown that CXCR4+ fibrocytes accumulate in the lung tissue of SSc patients (Figure 1) and that CSD peptide treatment inhibits the overexpression of CXCR4 by SSc monocytes [13] and their enhanced migration toward CXCL12 in vitro (Figure 4). Here, CXCL12 is linked to systemic sclerosis.